









市場行情
/
股票
/
nasdaq-inva
/

Innoviva Inc

INVA

18.590USD

-0.040-0.21%

收盤 08/04, 16:00（美東）報價延遲15分鐘

1.17B總市值

虧損本益比TTM



Innoviva Inc

18.590

-0.040-0.21%

概覽公司財務

Innoviva, Inc. 是一家多元化控股公司，擁有一系列專利和其他醫療資產。該公司的專利組合包括與葛蘭素集團有限公司 (GSK) 合作的呼吸系統資產，包括 RELVAR/BREO ELLIPTA（糠酸氟替卡松/維蘭特羅，FF/VI）和 ANORO ELLIPTA（溴化烏美溴銨/維蘭特羅，UMEC/VI）。根據長效β2激動劑 (LABA) 合作協議，該公司有權從 GSK 獲得 RELVAR/BREO、ELLIPTA 銷售的專利使用費。該公司的產品包括 GIAPREZA（血管緊張素 II），獲批用於增加感染性或其他分佈性休克成人患者的血壓，以及 XERAVA（埃拉環素），獲批用於治療成人複雜的腹腔內感染。第三款產品 XACDURO（以前稱爲舒巴坦-杜洛巴坦或 SUL-DUR）獲批用於治療成人不動桿菌引起的醫院內獲得性和呼吸機相關性肺炎。開發產品線包括佐利氟達星，這是一種用於治療單純性淋病的試驗性藥物，目前處於 III 期臨牀試驗階段。

公司簡介

公司代碼INVA

公司名稱Innoviva Inc

上市日期Oct 05, 2004

CEOMr. Pavel Raifeld

員工數量127

證券類型Ordinary Share

年結日Oct 05

公司地址1350 Old Bayshore Highway

城市BURLINGAME

上市交易所NASDAQ Global Select Consolidated

國家United States of America

郵編94010

電話16502389600

網址https://www.inva.com/

公司代碼INVA

上市日期Oct 05, 2004

CEOMr. Pavel Raifeld

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

Mr. Mark A. Dipaolo, Esq.

Chairman of the Board

130.71K

+10.18%

Dr. Sarah J. Schlesinger, M.D.

Lead Independent Director

130.71K

+10.18%

Dr. Sapna Srivastava, Ph.D.

Independent Director

44.10K

+11.98%

Ms. Marianne Y. Zhen, CPA

Chief Accounting Officer

27.71K

-3.46%

Mr. Pavel Raifeld

Chief Executive Officer

12.60K

+8.03%

Mr. Stephen Basso

Chief Financial Officer

4.63K

+31.73%

Mr. Jules A. Haimovitz

Independent Director

Dr. Odysseas D. Kostas, M.D.

Director

Mr. Derek A Small

Independent Director

名稱

名稱/職務

職務

持股

持股變動

Mr. Mark A. Dipaolo, Esq.

Chairman of the Board

130.71K

+10.18%

Dr. Sarah J. Schlesinger, M.D.

Lead Independent Director

130.71K

+10.18%

Dr. Sapna Srivastava, Ph.D.

Independent Director

44.10K

+11.98%

Ms. Marianne Y. Zhen, CPA

Chief Accounting Officer

27.71K

-3.46%

Mr. Pavel Raifeld

Chief Executive Officer

12.60K

+8.03%

Mr. Stephen Basso

Chief Financial Officer

4.63K

+31.73%

收入明細

FY2025Q1

FY2024

暫無數據

地區USD

名稱

營收

佔比

United States

88.63M

0.00%

業務

地區

暫無數據

股東統計

更新時間: 5月17日週六

持股股東

股東類型

持股股東

佔比

BlackRock Institutional Trust Company, N.A.

13.12%

The Vanguard Group, Inc.

10.01%

Dimensional Fund Advisors, L.P.

7.42%

Renaissance Technologies LLC

7.26%

Putnam Investment Management, L.L.C.

6.21%

Other

55.98%

持股股東

佔比

BlackRock Institutional Trust Company, N.A.

13.12%

The Vanguard Group, Inc.

10.01%

Dimensional Fund Advisors, L.P.

7.42%

Renaissance Technologies LLC

7.26%

Putnam Investment Management, L.L.C.

6.21%

Other

55.98%

股東類型

持股股東

佔比

Investment Advisor

45.92%

Investment Advisor/Hedge Fund

33.15%

Hedge Fund

23.37%

Research Firm

6.09%

Pension Fund

1.54%

Individual Investor

1.06%

Bank and Trust

0.43%

Sovereign Wealth Fund

0.19%

Venture Capital

0.10%

機構持股

更新時間: 7月1日週二

報告期間

機構數

持股數

持股佔比

持股變動

2025Q2

494

70.23M

111.87%

-7.08M

2025Q1

503

69.52M

110.75%

-9.29M

2024Q4

492

73.18M

116.75%

-6.44M

2024Q3

487

75.41M

120.47%

-5.51M

2024Q2

492

75.89M

121.41%

-5.03M

2024Q1

502

75.85M

119.80%

-4.18M

2023Q4

494

74.97M

116.88%

-1.82M

2023Q3

486

71.34M

109.51%

-8.23M

2023Q2

482

72.90M

111.23%

-6.11M

2023Q1

482

72.87M

106.90%

-10.58M

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

BlackRock Institutional Trust Company, N.A.

8.24M

13.12%

-285.10K

-3.34%

Mar 31, 2025

The Vanguard Group, Inc.

6.28M

10.01%

-16.60K

-0.26%

Mar 31, 2025

Dimensional Fund Advisors, L.P.

4.66M

7.42%

-259.73K

-5.28%

Mar 31, 2025

Renaissance Technologies LLC

4.56M

7.26%

+295.50K

+6.93%

Mar 31, 2025

Putnam Investment Management, L.L.C.

3.90M

6.21%

-462.44K

-10.61%

Mar 31, 2025

Sarissa Capital Management, L.P.

2.82M

4.49%

-4.46M

-61.30%

Mar 31, 2025

State Street Global Advisors (US)

2.36M

3.77%

-94.90K

-3.86%

Mar 31, 2025

Systematic Financial Management, L.P.

2.07M

3.3%

+42.18K

+2.08%

Mar 31, 2025

Millennium Management LLC

1.68M

2.67%

+1.28M

+318.37%

Mar 31, 2025

American Century Investment Management, Inc.

1.68M

2.67%

+251.38K

+17.65%

Mar 31, 2025

持股ETF

更新時間: 8月2日週六

機構名稱

佔比

Invesco Pharmaceuticals ETF

2.84%

ETC 6 Meridian Small Cap Equity ETF

2.56%

First Trust Horizon Managed Vol Small/Mid ETF

2.39%

SPDR S&P Pharmaceuticals ETF

2.04%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.44%

Invesco S&P SmallCap Low Volatility ETF

1.25%

Acquirers Small and Micro Deep Value ETF

0.94%

VictoryShares US Small Mid Cap Value Momentum ETF

0.82%

Invesco S&P SmallCap Health Care ETF

0.79%

Pacer US Small Cap Cash Cows Growth Leaders ETF

0.76%

Invesco Pharmaceuticals ETF

佔比2.84%

ETC 6 Meridian Small Cap Equity ETF

佔比2.56%

First Trust Horizon Managed Vol Small/Mid ETF

佔比2.39%

SPDR S&P Pharmaceuticals ETF

佔比2.04%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

佔比1.44%

Invesco S&P SmallCap Low Volatility ETF

佔比1.25%

Acquirers Small and Micro Deep Value ETF

佔比0.94%

VictoryShares US Small Mid Cap Value Momentum ETF

佔比0.82%

Invesco S&P SmallCap Health Care ETF

佔比0.79%

Pacer US Small Cap Cash Cows Growth Leaders ETF

佔比0.76%

分紅派息

近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股

公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

KeyAI

